ArticleJournal of gastroenterology2024

CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.

Masayuki Ueno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.